A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies

Joshua R. Gonzalez, Melissa A. Laudano, Tara R. McCann, James M. McKiernan, Mitchell C. Benson

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these "high-risk" men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalWorld Journal of Urology
Issue number5
StatePublished - 2008
Externally publishedYes


  • Adjuvant therapy
  • High risk
  • Prostate
  • Prostatic neoplasia
  • Radical prostatectomy
  • Survival

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies'. Together they form a unique fingerprint.

Cite this